Bayer plc

Bayer House, Strawberry Hill, Newbury, Berkshire, RG14 1JA
Telephone: +44 (0)1635 563 000
Fax: +44 (0)1635 563 393
WWW: http://www.bayer.co.uk
Summary of Product Characteristics last updated on the eMC: 05/06/2008
SPC Adalat LA 30

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 05/06/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   02-May-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 7 (MA Holder) has been updated with the 'Bayer Schering Pharma' trading sytle.
Section 10 (Date of Revision of the Text) has been updated with the date of approval of the above. 
Updated on 24/01/2008 and displayed until 05/06/2008
Reasons for adding or updating:
  • New individual SPC (was previously included in combined SPC)
Date of revision of text on the SPC:   09/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Submission of an individual SmPC, previously a joint SmPC for 20/30/60.

Global Labelling Harmonization SmPC update (sections 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2, 5.3) and update to excipient information (SmPC section 6.1). 

Active Ingredients/Generics

 
   nifedipine


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk